Priority review vouchers: An inefficient and dangerous way to promote neglected-disease drug development

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 6, 2009, Pages 573-575

  Kesselheim, A S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN; ARTEMETHER PLUS BENFLUMETOL; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; DIETHYLCARBAMAZINE; EFLORNITHINE; ESOMEPRAZOLE; ETHAMBUTOL; ISONIAZID; IVERMECTIN; MEBENDAZOLE; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; OFLOXACIN; OMEPRAZOLE; OXAMNIQUINE; PAROMOMYCIN; PENTAMIDINE; PRAZIQUANTEL; PYRAZINAMIDE; RIFAMPICIN; STIBOGLUCONATE SODIUM; STREPTOMYCIN; SURAMIN; TETRACYCLINE; TRICLABENDAZOLE; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; BURULI ULCER; CHOLERA; DENGUE; DRACUNCULIASIS; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; FASCIOLIASIS; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HEALTH PROGRAM; HELMINTHIASIS; INFECTION; LAW; LEISHMANIASIS; LEPROSY; LYMPHATIC FILARIASIS; MALARIA; MEDICAL DECISION MAKING; ONCHOCERCIASIS; ORAL REHYDRATION THERAPY; PRIORITY JOURNAL; SCHISTOSOMIASIS; SHORT SURVEY; TRACHOMA; TROPICAL DISEASE; TUBERCULOSIS; YAWS;

ANTI-INFECTIVE AGENTS; BIOTERRORISM; COMMUNICABLE DISEASE CONTROL; DRUG APPROVAL; DRUG INDUSTRY; FINANCING, GOVERNMENT; HEALTH PRIORITIES; HUMANS; UNITED STATES; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINES;

EID: 66249099919     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.50     Document Type: Short Survey

References (10)

1. Ridley, D.B., Grabowski, H.G. & Moe, J.L. Developing drugs for developing countries. Health Aff. 25, 313-324 (2006).
2. Kesselheim, A.S., Fischer, M.A. & Avorn, J. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on Medicaid spending. Health Aff. 25,1637-1647 (2006).
3. Nwaka, S. & Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5, 941-955 (2006).
4. Outterson, K. Should access to medicines and TRIPS flexibilities be limited to specific diseases? Am. J. Law Med. 34, 279-338 (2008).
5. Pécoul, B. New drugs for neglected diseases: from pipeline to patients. PLoS Med. 1:e6 (2004).
6. Kesselheim, A.S. Drug development for neglected diseases - the trouble with FDA review vouchers. N. Engl. J. Med. 359, 1981- 1983 (2008).
7. Carpenter, D., Zucker, E.J. & Avorn, J. Drug-review deadlines and safety problems. N. Engl. J. Med. 358, 1354-1361 (2008).
8. Nardinelli, C., Lanthier, M. & Temple, R. Drug-review deadlines and safety problems [letter]. N.Engl. J. Med. 359, 95-96 (2008).
9. Hale, V.G., Woo, K. & Lipton, H.L. Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world. Health Aff. 24, 1057-1063 (2005).
10. Boseley, S. Drug giant GlaxoSmithKline pledges cheap medicine for world's poor. Guardian (London), 13 February 2009.